ERBB2 and breast cancer: The OlympiA trial is a pivotal trial that evaluated the efficacy of adjuvant treatment with olaparib, a PARP inhibitor, compared to placebo in patients with non-metastatic, germline BRCA mutated (gBRCAm), high risk, HER2-negative primary breast cancer [13].